Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5371441 | 1.00 | MEN1 (0.45) | MEN1KMT2ANPC1ADRB2ADRB1 | |
| SCHEMBL5359451 | 1.00 | MEN1 (0.45) | MEN1KMT2ANPC1ADRB2ADRB1 | |
| SCHEMBL5359732 | 0.95 | NPC1 (0.49) | MEN1KMT2ANPC1ADRB2ADRB1 | |
| SCHEMBL5359736 | 0.95 | NPC1 (0.49) | MEN1KMT2ANPC1ADRB2ADRB1 | |
| SCHEMBL5359727 | 0.95 | NPC1 (0.49) | MEN1KMT2ANPC1ADRB2ADRB1 | |
| SCHEMBL5369871 | 0.94 | NPC1 (0.41) | MEN1KMT2ANPC1ADRB2ADRB1 | |
| SCHEMBL1382995 | 0.94 | NPC1 (0.41) | MEN1KMT2ANPC1ADRB2ADRB1 | |
| SCHEMBL1382990 | 0.94 | NPC1 (0.41) | MEN1KMT2ANPC1ADRB2ADRB1 | |
| SCHEMBL5366687 | 0.92 | NPC1 (0.56) | MEN1KMT2ANPC1ADRB2ADRB1 | |
| SCHEMBL5361309 | 0.92 | NPC1 (0.44) | MEN1KMT2ANPC1ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253165-B2 | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-07 | — | — | US | claimed |
| US-20050107377-A1 | Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTIALS INC. (US) | 2005-05-19 | — | — | US | claimed |
| EP-1216244-B1 | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMA INC (US) | 2003-08-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107377-A1 | Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | DRD4, DRD2, DRD1 | MEN1 4880/4885KMT2A 2351/4885NPC1 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.